Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Editas Medicine stock | $38.47

Learn how to easily invest in Editas Medicine stock.

Editas Medicine Inc is a biotechnology business based in the US. Editas Medicine shares (EDIT) are listed on the NASDAQ and all prices are listed in US Dollars. Editas Medicine employs 235 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Editas Medicine

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EDIT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Editas Medicine stock price (NASDAQ: EDIT)

Use our graph to track the performance of EDIT stocks over time.

Editas Medicine shares at a glance

Information last updated 2021-10-17.
Latest market close$38.47
52-week range$27.12 - $99.95
50-day moving average $53.25
200-day moving average $45.27
Wall St. target price$53.08
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.58

Buy Editas Medicine shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Editas Medicine stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Editas Medicine price performance over time

Historical closes compared with the close of $38.47 from 2021-10-21

1 week (2021-10-15) 1.18%
1 month (2021-09-22) -34.92%
3 months (2021-07-22) -10.56%
6 months (2021-04-22) 6.01%
1 year (2020-10-22) 19.27%
2 years (2019-10-22) 89.51%
3 years (2018-10-22) 43.49%
5 years (2016-10-21) 151.11%

Editas Medicine financials

Revenue TTM $81.1 million
Gross profit TTM $-67,264,000
Return on assets TTM -14.98%
Return on equity TTM -32.05%
Profit margin -205.41%
Book value $9.00
Market capitalisation $2.6 billion

TTM: trailing 12 months

Shorting Editas Medicine shares

There are currently 6.9 million Editas Medicine shares held short by investors – that's known as Editas Medicine's "short interest". This figure is 1.4% down from 7.0 million last month.

There are a few different ways that this level of interest in shorting Editas Medicine shares can be evaluated.

Editas Medicine's "short interest ratio" (SIR)

Editas Medicine's "short interest ratio" (SIR) is the quantity of Editas Medicine shares currently shorted divided by the average quantity of Editas Medicine shares traded daily (recently around 2.0 million). Editas Medicine's SIR currently stands at 3.38. In other words for every 100,000 Editas Medicine shares traded daily on the market, roughly 3380 shares are currently held short.

However Editas Medicine's short interest can also be evaluated against the total number of Editas Medicine shares, or, against the total number of tradable Editas Medicine shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Editas Medicine's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Editas Medicine shares in existence, roughly 100 shares are currently held short) or 0.1027% of the tradable shares (for every 100,000 tradable Editas Medicine shares, roughly 103 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Editas Medicine.

Find out more about how you can short Editas Medicine stock.

Editas Medicine share dividends

We're not expecting Editas Medicine to pay a dividend over the next 12 months.

Editas Medicine share price volatility

Over the last 12 months, Editas Medicine's shares have ranged in value from as little as $27.12 up to $99.95. A popular way to gauge a stock's volatility is its "beta".

EDIT.US volatility(beta: 2.07)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Editas Medicine's is 2.0651. This would suggest that Editas Medicine's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Editas Medicine overview

Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc.

Frequently asked questions

What percentage of Editas Medicine is owned by insiders or institutions?
Currently 0.342% of Editas Medicine shares are held by insiders and 76.029% by institutions.
How many people work for Editas Medicine?
Latest data suggests 235 work at Editas Medicine.
When does the fiscal year end for Editas Medicine?
Editas Medicine's fiscal year ends in December.
Where is Editas Medicine based?
Editas Medicine's address is: 11 Hurley Street, Cambridge, MA, United States, 02141
What is Editas Medicine's ISIN number?
Editas Medicine's international securities identification number is: US28106W1036
What is Editas Medicine's CUSIP number?
Editas Medicine's Committee on Uniform Securities Identification Procedures number is: 28106W103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site